Kaspars Kupics
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kaspars Kupics has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
Bruno Schwagten
Electrophysiology Unit, ZNA Middelheim, Antwerp, Belgium
4 shared publicationsCarlo de Asmundis
Heart Rhythm Management Centre, Postgraduate course in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium
4 shared publicationsDirk Stockman
Electrophysiology Unit, ZNA Middelheim, Antwerp, Belgium
4 shared publicationsJeroen De Cocker
Electrophysiology Unit, ZNA Middelheim, Antwerp, Belgium
4 shared publications- Andrejs Erglis
Pauls Stradins Clinical University Hospital, Riga, Latvia
3 shared publications - Erwin Ströker
Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel – Vrije Universiteit Brussel, Brussels, Belgium
3 shared publications
Latest Publications
- Open Access
Initial Experience with Standalone Thoracoscopic Left Atrial Appendage Occlusion Using AtriClip Pro2: A Single-Center Retrospective Cohort Study in Latvia
Background and Objectives: Left atrial appendage (LAA) closure is an established strategy for stroke prevention in selected patients with atrial fibrillation (AF), particularly when long-term oral anticoagulation (OAC) is contraindicated. Thoracoscopic epicardial LAA occlusion using the AtriClip Pro2 device provides a minimally invasive surgical approach; however, evidence for standalone use remains limited. This study aimed to describe the initial feasibility and early clinical outcomes of standalone thoracoscopic LAA occlusion using AtriClip Pro2 in Latvia. Materials and Methods: We performed a single-center retrospective observational study including all consecutive patients who underwent standalone thoracoscopic LAA occlusion at the Department of Cardiac Surgery, Pauls Stradins Clinical University Hospital, between December 2024 and March 2026. Baseline characteristics, procedural outcomes, perioperative complications, rehospitalizations, and antithrombotic therapy status were assessed. LAA closure was assessed by transesophageal echocardiography (TEE). Results: Fourteen patients were included. Mean age was 63.6 ± 16.7 years (median 67.0; IQR 54.8–76.8), and 64.3% were female. Thoracoscopic completion was achieved in 13/14 patients (92.9%; 95% CI 68.5–98.7%); one patient (7.1%) required conversion to median sternotomy because of intraoperative bleeding. Complete LAA exclusion without residual flow or stump was documented in all 14 patients (100%; 95% CI 78.5–100%). No perioperative stroke or mortality occurred. At three months, follow-up data were available for all patients, and antithrombotic therapy had been discontinued in 12/14 patients (85.7%). Conclusions: This small, heterogeneous, single-center series supports the technical feasibility of standalone thoracoscopic AtriClip Pro2 implantation in selected patients. These encouraging early findings warrant further evaluation in larger cohorts with longer clinical follow-up and standardized postoperative imaging.
Open AccessInitial Experience with Standalone Thoracoscopic Left Atrial Appendage Occlusion Using AtriClip Pro2: A Single-Center Retrospective Cohort Study in Latvia
Background and Objectives: Left atrial appendage (LAA) closure is an established strategy for stroke prevention in selected patients with atrial fibrillation (AF), particularly when long-term oral anticoagulation (OAC) is contraindicated. Thoracoscopic epicardial LAA occlusion using the AtriClip Pro2 device provides a minimally invasive surgical approach; however, evidence for standalone use remains limited. This study aimed to describe the initial feasibility and early clinical outcomes of standalone thoracoscopic LAA occlusion using AtriClip Pro2 in Latvia. Materials and Methods: We performed a single-center retrospective observational study including all consecutive patients who underwent standalone thoracoscopic LAA occlusion at the Department of Cardiac Surgery, Pauls Stradins Clinical University Hospital, between December 2024 and March 2026. Baseline characteristics, procedural outcomes, perioperative complications, rehospitalizations, and antithrombotic therapy status were assessed. LAA closure was assessed by transesophageal echocardiography (TEE). Results: Fourteen patients were included. Mean age was 63.6 ± 16.7 years (median 67.0; IQR 54.8–76.8), and 64.3% were female. Thoracoscopic completion was achieved in 13/14 patients (92.9%; 95% CI 68.5–98.7%); one patient (7.1%) required conversion to median sternotomy because of intraoperative bleeding. Complete LAA exclusion without residual flow or stump was documented in all 14 patients (100%; 95% CI 78.5–100%). No perioperative stroke or mortality occurred. At three months, follow-up data were available for all patients, and antithrombotic therapy had been discontinued in 12/14 patients (85.7%). Conclusions: This small, heterogeneous, single-center series supports the technical feasibility of standalone thoracoscopic AtriClip Pro2 implantation in selected patients. These encouraging early findings warrant further evaluation in larger cohorts with longer clinical follow-up and standardized postoperative imaging.
- Open Access
- 6 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (9) , 1398
Integrating Patient-Reported Outcomes into Clinical Pathways in Atrial Fibrillation: A Framework Aligned with the AF-CARE Model
Background: Atrial fibrillation (AF) significantly impacts the clinical and financial burden of healthcare systems worldwide. Patient-reported outcomes (PROMs) are considered a core element of patient-centered care. However, the integration of PROMs into AF clinical pathways remains limited. Objectives: In this study, we aimed to develop a policy-oriented framework for integrating PROMs into AF management, building on QoL assessment and the AF-CARE pathway. Methods: We compared the selected instruments (AFEQT, SF-36, EQ-5D, and AFSS) to examine how different QoL domains are represented. We then considered how the missing domains relate to routine care and healthcare delivery. On this basis, we constructed a conceptual framework linking PROM domains with clinical and policy decisions, as well as with diagnostic and follow-up strategies in AF. Results: Existing PROMs capture symptom burden reasonably well, but they do not fully reflect several domains that shape the daily experience of patients with AF, including cognition, sleep quality, sexual health, and economic burden. The proposed framework places PROMs within the AF-CARE components and illustrates how they can be used in routine practice—not only for long-term monitoring, but also to improve clinical decision-making, and better align with value-based healthcare strategies at both the clinical and system levels. It also outlines a practical approach to incorporating PROMs into everyday care and into broader health-system decision-making. Conclusions: Integrating PROMs into AF-CARE requires a system-level redesign rather than isolated tool implementation. Within the proposed framework, the question is no longer whether PROMs should be used in AF care, but how to integrate them in a way that meaningfully influences clinical decisions and patient outcomes.
- 6 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (9) , 1398
Open AccessIntegrating Patient-Reported Outcomes into Clinical Pathways in Atrial Fibrillation: A Framework Aligned with the AF-CARE Model
Background: Atrial fibrillation (AF) significantly impacts the clinical and financial burden of healthcare systems worldwide. Patient-reported outcomes (PROMs) are considered a core element of patient-centered care. However, the integration of PROMs into AF clinical pathways remains limited. Objectives: In this study, we aimed to develop a policy-oriented framework for integrating PROMs into AF management, building on QoL assessment and the AF-CARE pathway. Methods: We compared the selected instruments (AFEQT, SF-36, EQ-5D, and AFSS) to examine how different QoL domains are represented. We then considered how the missing domains relate to routine care and healthcare delivery. On this basis, we constructed a conceptual framework linking PROM domains with clinical and policy decisions, as well as with diagnostic and follow-up strategies in AF. Results: Existing PROMs capture symptom burden reasonably well, but they do not fully reflect several domains that shape the daily experience of patients with AF, including cognition, sleep quality, sexual health, and economic burden. The proposed framework places PROMs within the AF-CARE components and illustrates how they can be used in routine practice—not only for long-term monitoring, but also to improve clinical decision-making, and better align with value-based healthcare strategies at both the clinical and system levels. It also outlines a practical approach to incorporating PROMs into everyday care and into broader health-system decision-making. Conclusions: Integrating PROMs into AF-CARE requires a system-level redesign rather than isolated tool implementation. Within the proposed framework, the question is no longer whether PROMs should be used in AF care, but how to integrate them in a way that meaningfully influences clinical decisions and patient outcomes.
- Open Access
Waiting Time for Pulmonary Vein Isolation: A Single-Center Retrospective Cohort Study of Atrial Fibrillation Progression and Complications
Background and Objectives: Pulmonary vein isolation (PVI) is an established rhythm control strategy for atrial fibrillation (AF). In many healthcare systems, increasing demand and limited procedural capacity have resulted in prolonged waiting times. The primary aim of this study was to evaluate the association between waiting time for PVI and AF progression. Secondary aims were to assess the relationship between waiting time and AF-related complications, healthcare utilization, and clinical factors associated with higher risk of progression. Materials and Methods: We performed a single-center observational cohort study of patients on the waiting list for PVI at Pauls Stradiņš Clinical University Hospital between 2016 and 2023. Results: A total of 341 patients completed structured ambulatory follow-up to assess the complication and progression rates of AF. The mean age was 64.8 ± 10.5 years, 50.9% were male, and the median waiting time was 37.2 months (IQR 15.0–61.3). AF progression occurred in 25.7% (n = 88) of patients, with longer waiting time independently associated with progression (OR, 1.017 per month; 95% CI, 1.006–1.028; p < 0.05). Electrical cardioversion during the waiting period was associated with a lower likelihood of progression (OR, 0.32; p = 0.029), and Class IC antiarrhythmic therapy was associated with reduced risk of AF progression (HR 0.78; p = 0.013). During follow-up, 45.2% of patients were hospitalized for AF paroxysms, 29.6% underwent electrical cardioversion, and 13.5% experienced complications including stroke and heart failure decompensation. Left atrial volume index and left ventricular ejection fraction were inversely correlated (ρ = −0.355, p < 0.05), but neither was associated with waiting time. Conclusions: Longer waiting times for PVI are associated with AF progression and substantial interim healthcare utilization due to complications. Strategies to prioritize higher-risk patients may help prevent disease progression and reduce complication burden.
Open AccessWaiting Time for Pulmonary Vein Isolation: A Single-Center Retrospective Cohort Study of Atrial Fibrillation Progression and Complications
Background and Objectives: Pulmonary vein isolation (PVI) is an established rhythm control strategy for atrial fibrillation (AF). In many healthcare systems, increasing demand and limited procedural capacity have resulted in prolonged waiting times. The primary aim of this study was to evaluate the association between waiting time for PVI and AF progression. Secondary aims were to assess the relationship between waiting time and AF-related complications, healthcare utilization, and clinical factors associated with higher risk of progression. Materials and Methods: We performed a single-center observational cohort study of patients on the waiting list for PVI at Pauls Stradiņš Clinical University Hospital between 2016 and 2023. Results: A total of 341 patients completed structured ambulatory follow-up to assess the complication and progression rates of AF. The mean age was 64.8 ± 10.5 years, 50.9% were male, and the median waiting time was 37.2 months (IQR 15.0–61.3). AF progression occurred in 25.7% (n = 88) of patients, with longer waiting time independently associated with progression (OR, 1.017 per month; 95% CI, 1.006–1.028; p < 0.05). Electrical cardioversion during the waiting period was associated with a lower likelihood of progression (OR, 0.32; p = 0.029), and Class IC antiarrhythmic therapy was associated with reduced risk of AF progression (HR 0.78; p = 0.013). During follow-up, 45.2% of patients were hospitalized for AF paroxysms, 29.6% underwent electrical cardioversion, and 13.5% experienced complications including stroke and heart failure decompensation. Left atrial volume index and left ventricular ejection fraction were inversely correlated (ρ = −0.355, p < 0.05), but neither was associated with waiting time. Conclusions: Longer waiting times for PVI are associated with AF progression and substantial interim healthcare utilization due to complications. Strategies to prioritize higher-risk patients may help prevent disease progression and reduce complication burden.
- Open Access
- 27 October 2025
- Published by MDPI AG in Preprints.org
Real-World Use and Impact of Direct Oral Anticoagulants in Cardioembolic Stroke Patients with Atrial Fibrillation
Background and Objectives: Atrial fibrillation (AF) is a primary cause of cardioembolic stroke (CS). AF-related mortality increased substantially in Eastern Europe in the last decade. While direct oral anticoagulants (DOACs) are effective for stroke prevention, non-adherence is a major clinical problem. This study aimed to investigate real-world DOAC usage among AF patients presenting with stroke and to evaluate the impact of prior DOAC therapy on stroke severity. Materials and Methods: This retrospective study analysed data from CS patients with AF admitted to the two largest Latvian university hospitals from January 2022 to December 2024. Secondly, a propensity-matched analysis was performed on a single-centre cohort to compare outcomes between patients receiving DOAC therapy and those not. Results: Of 2773 patients enrolled, the largest subgroup (45%) consisted of patients with known AF who were not on appropriate anticoagulation therapy before the stroke event. The propensity-matched analysis based on demographics, arrival time, AF type, and CHA 2 DS 2 -VA score (163 patients per group) revealed that patients taking DOACs presented with significantly milder strokes than non-users (mean admission NIHSS: 9.8 vs. 11.6, p=0.009). 40.5% of DOAC users received a reduced DOAC dose, and in 22.1% the DOAC dose was reduced inadequately. Stroke patients on DOAC therapy had significantly larger left atrial volume indices (LAVI) than non-users (56.4 vs. 48.0, respectively; p=0.004). Conclusions: Non-adherence to DOACs represents a substantial contributor to the CS burden. Prior DOAC use is associated with significantly reduced initial stroke severity, highlighting the protective benefit of therapy even when it fails to prevent an event.
- 27 October 2025
- Published by MDPI AG in Preprints.org
Open AccessReal-World Use and Impact of Direct Oral Anticoagulants in Cardioembolic Stroke Patients with Atrial Fibrillation
Background and Objectives: Atrial fibrillation (AF) is a primary cause of cardioembolic stroke (CS). AF-related mortality increased substantially in Eastern Europe in the last decade. While direct oral anticoagulants (DOACs) are effective for stroke prevention, non-adherence is a major clinical problem. This study aimed to investigate real-world DOAC usage among AF patients presenting with stroke and to evaluate the impact of prior DOAC therapy on stroke severity. Materials and Methods: This retrospective study analysed data from CS patients with AF admitted to the two largest Latvian university hospitals from January 2022 to December 2024. Secondly, a propensity-matched analysis was performed on a single-centre cohort to compare outcomes between patients receiving DOAC therapy and those not. Results: Of 2773 patients enrolled, the largest subgroup (45%) consisted of patients with known AF who were not on appropriate anticoagulation therapy before the stroke event. The propensity-matched analysis based on demographics, arrival time, AF type, and CHA 2 DS 2 -VA score (163 patients per group) revealed that patients taking DOACs presented with significantly milder strokes than non-users (mean admission NIHSS: 9.8 vs. 11.6, p=0.009). 40.5% of DOAC users received a reduced DOAC dose, and in 22.1% the DOAC dose was reduced inadequately. Stroke patients on DOAC therapy had significantly larger left atrial volume indices (LAVI) than non-users (56.4 vs. 48.0, respectively; p=0.004). Conclusions: Non-adherence to DOACs represents a substantial contributor to the CS burden. Prior DOAC use is associated with significantly reduced initial stroke severity, highlighting the protective benefit of therapy even when it fails to prevent an event.
- Open Access
Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation: Short-Term Follow-Up Study
Background and Objectives: Atrial fibrillation (AF) significantly impacts the quality of life (QoL) of affected individuals. Pulmonary vein isolation (PVI) has emerged as a therapeutic approach to manage AF and improve QoL. This study aimed to assess the QoL in patients with AF undergoing PVI. Methods and Materials: A total of 97 AF patients undergoing PVI (radiofrequency 52.6% (n = 51) and cryoablation 47.4% (n = 46)) at Pauls Stradins Clinical University Hospital were included in this study. QoL was measured using the 36-Item Short-Form Survey (SF-36) before PVI and during a follow-up period of 5.98 ± 1.97 months. Results: This study consisted of 60.8% (n = 59) males, with a mean age of 60.06 ± 11.61 years. A total of 67.0% (n = 65) of patients had paroxysmal AF, and 33.0% (n = 32) had persistent AF. The SF-36 questionnaire revealed major improvements across multiple QoL domains post-PVI, reaching a statistical significance of p < 0.01. Patient factors, such as female gender ([estimate 21.26, 95% CI (7.18, 35.35)], p < 0.01), persistent AF ([estimate 15.49, 95% CI (2.83, 28.15)], p = 0.02), and restored sinus rhythm ([estimate 14.35, 95% CI (1.65, 27.06)], p = 0.03), were associated with significantly improved QoL. Conclusions: PVI in patients with AF positively influences various dimensions of QoL, as evidenced by significant improvement across multiple SF-36 domains. These findings emphasize worsened QoL in patients with AF and the potential benefits of PVI enhancing the overall wellbeing of individuals with AF.
Open AccessQuality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation: Short-Term Follow-Up Study
Background and Objectives: Atrial fibrillation (AF) significantly impacts the quality of life (QoL) of affected individuals. Pulmonary vein isolation (PVI) has emerged as a therapeutic approach to manage AF and improve QoL. This study aimed to assess the QoL in patients with AF undergoing PVI. Methods and Materials: A total of 97 AF patients undergoing PVI (radiofrequency 52.6% (n = 51) and cryoablation 47.4% (n = 46)) at Pauls Stradins Clinical University Hospital were included in this study. QoL was measured using the 36-Item Short-Form Survey (SF-36) before PVI and during a follow-up period of 5.98 ± 1.97 months. Results: This study consisted of 60.8% (n = 59) males, with a mean age of 60.06 ± 11.61 years. A total of 67.0% (n = 65) of patients had paroxysmal AF, and 33.0% (n = 32) had persistent AF. The SF-36 questionnaire revealed major improvements across multiple QoL domains post-PVI, reaching a statistical significance of p < 0.01. Patient factors, such as female gender ([estimate 21.26, 95% CI (7.18, 35.35)], p < 0.01), persistent AF ([estimate 15.49, 95% CI (2.83, 28.15)], p = 0.02), and restored sinus rhythm ([estimate 14.35, 95% CI (1.65, 27.06)], p = 0.03), were associated with significantly improved QoL. Conclusions: PVI in patients with AF positively influences various dimensions of QoL, as evidenced by significant improvement across multiple SF-36 domains. These findings emphasize worsened QoL in patients with AF and the potential benefits of PVI enhancing the overall wellbeing of individuals with AF.
- Top Cited Papers
- 30 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (36) , 3314-3414
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
- 30 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (36) , 3314-3414
Top Cited Papers2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
- Open Access
- 30 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (12) , ytab480
A case report of pulmonary vein isolation performed in a patient with polysplenia and interrupted inferior vena cava
Background: Pulmonary vein isolation (PVI) has entrenched itself as one of the main approaches for the treatment of paroxysmal symptomatic atrial fibrillation (AF). Pulmonary vein isolation prevents focal triggers from pulmonary veins from initiating AF paroxysms. As standard—PVI is performed through the inferior vena cava (IVC) approach, through the femoral vein. However, there are conditions when this approach is not appropriate or is not available. Case summary: We report a case of a 53-year-old male who was referred to Pauls Stradins Clinical University Hospital for PVI due to worsening AF. Due to the rare anatomical variant of the venous system, the standard approach to PVI could not be applied. Interrupted cava inferior did not allow for femoral vein and IVC access. We had to figure out a different path—a combination of internal jugular and subclavian veins was used. Transseptal puncture was performed under transoesophageal echocardiography (TOE) control with a puncture needle stiletto. Pulmonary veins were isolated successfully, no complications were observed, and the patient was discharged in sinus rhythm. Discussion: In some patients, PVI cannot be done through the standard IVC approach. In such cases, a different venous access must be chosen. Our patient had a rare variant of interrupted IVC and we had to use superior vena cava approach for the procedure. The difficulty of this approach is that procedure instruments are not designed for non-standard venous access; however, a combined use of TOE, general anaesthesia, and contact force-guided ablation has succeeded in isolating patients’ pulmonary veins.
- 30 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (12) , ytab480
Open AccessA case report of pulmonary vein isolation performed in a patient with polysplenia and interrupted inferior vena cava
Background: Pulmonary vein isolation (PVI) has entrenched itself as one of the main approaches for the treatment of paroxysmal symptomatic atrial fibrillation (AF). Pulmonary vein isolation prevents focal triggers from pulmonary veins from initiating AF paroxysms. As standard—PVI is performed through the inferior vena cava (IVC) approach, through the femoral vein. However, there are conditions when this approach is not appropriate or is not available. Case summary: We report a case of a 53-year-old male who was referred to Pauls Stradins Clinical University Hospital for PVI due to worsening AF. Due to the rare anatomical variant of the venous system, the standard approach to PVI could not be applied. Interrupted cava inferior did not allow for femoral vein and IVC access. We had to figure out a different path—a combination of internal jugular and subclavian veins was used. Transseptal puncture was performed under transoesophageal echocardiography (TOE) control with a puncture needle stiletto. Pulmonary veins were isolated successfully, no complications were observed, and the patient was discharged in sinus rhythm. Discussion: In some patients, PVI cannot be done through the standard IVC approach. In such cases, a different venous access must be chosen. Our patient had a rare variant of interrupted IVC and we had to use superior vena cava approach for the procedure. The difficulty of this approach is that procedure instruments are not designed for non-standard venous access; however, a combined use of TOE, general anaesthesia, and contact force-guided ablation has succeeded in isolating patients’ pulmonary veins.
- 29 April 2019
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 42 (7) , 868-873
Over‐the‐needle trans‐septal access using the cryoballoon delivery sheath and dilator in atrial fibrillation ablation
Background: In the setting of second‐generation cryoballoon (CB2) ablation, left atrial (LA) access is generally achieved using a standard sheath (SS) that is exchanged for the 15Fr cryoballoon delivery sheath (CBS) and dilator over a long wire (CBS over‐the‐wire technique, CBS‐W). Our objective was to evaluate the direct use of the CBS to gain LA access, by advancing the latter over the trans‐septal needle (CBS over‐the‐needle technique, CBS‐N), under transesophageal echocardiographic (TEE) guidance.Methods: Consecutive patients who underwent CB2 ablation with the CBS‐N technique were evaluated for feasibility of gaining LA access using TEE guidance and fluoroscopy views. Complications related to the LA access were compared with a matched CBS‐W control group. Subanalysis (30 CBS‐W vs 30 CBS‐N patients) evaluated time‐to‐LA of the CBS: time from superior vena cava (with SS vs CBS) to LA insertion of the CBS, after exchange or directly, respectively.Results: LA access could be achieved in all 505 patients of the CBS‐N group, without technique modification or additional equipment. Challenging interatrial septa were noted in 13% of these patients: previous atrial septal defect repair (1%), hypermobile (10%), aneurysmal (1%), and abnormally thickened/fibrotic (1%). Incidence of complications was similar to the CBS‐W group. Subanalysis showed a shorter time‐to‐LA in the CBS‐N versus CBS‐W group, 72 ± 46 seconds versus 293 ± 180 seconds, P < .001.Conclusions: Our study showed that the CBS‐N technique is feasible and safe under echocardiographic guidance. Without sheath exchange, it simplifies the CB2 procedure, is less costly, time sparing, and might reduce the risk of air embolism.
- 29 April 2019
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 42 (7) , 868-873
Over‐the‐needle trans‐septal access using the cryoballoon delivery sheath and dilator in atrial fibrillation ablation
Background: In the setting of second‐generation cryoballoon (CB2) ablation, left atrial (LA) access is generally achieved using a standard sheath (SS) that is exchanged for the 15Fr cryoballoon delivery sheath (CBS) and dilator over a long wire (CBS over‐the‐wire technique, CBS‐W). Our objective was to evaluate the direct use of the CBS to gain LA access, by advancing the latter over the trans‐septal needle (CBS over‐the‐needle technique, CBS‐N), under transesophageal echocardiographic (TEE) guidance.Methods: Consecutive patients who underwent CB2 ablation with the CBS‐N technique were evaluated for feasibility of gaining LA access using TEE guidance and fluoroscopy views. Complications related to the LA access were compared with a matched CBS‐W control group. Subanalysis (30 CBS‐W vs 30 CBS‐N patients) evaluated time‐to‐LA of the CBS: time from superior vena cava (with SS vs CBS) to LA insertion of the CBS, after exchange or directly, respectively.Results: LA access could be achieved in all 505 patients of the CBS‐N group, without technique modification or additional equipment. Challenging interatrial septa were noted in 13% of these patients: previous atrial septal defect repair (1%), hypermobile (10%), aneurysmal (1%), and abnormally thickened/fibrotic (1%). Incidence of complications was similar to the CBS‐W group. Subanalysis showed a shorter time‐to‐LA in the CBS‐N versus CBS‐W group, 72 ± 46 seconds versus 293 ± 180 seconds, P < .001.Conclusions: Our study showed that the CBS‐N technique is feasible and safe under echocardiographic guidance. Without sheath exchange, it simplifies the CB2 procedure, is less costly, time sparing, and might reduce the risk of air embolism.
- 11 July 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (3) , 434-439
Value of ultrasound for access guidance and detection of subclinical vascular complications in the setting of atrial fibrillation cryoballoon ablation
Vascular complications are the most common complications of atrial fibrillation (AF) ablation. Cryoballoon (CB) ablation for AF needs the insertion of a large 15 Fr sheath in the femoral vein. Our aim was to investigate the impact of vascular ultrasound (US) in guiding access and evaluating post-procedural subclinical complications in a large, multi-centre patient cohort that underwent CB ablation. A total cohort of 1435 consecutive patients were subdivided in 870 US −/−, 265 US −/+, and 300 US +/+ patients depending on US performance for: venipuncture guidance/post-procedural evaluation. Major clinical complications (requiring intervention and/or prolonged stay) were assessed. Irrespective of the clinical status, major US events were systematically determined in the subgroups with US evaluation 1 day post-procedure, if evidence of inadvertent artery puncture/cannulation (communication between artery and collection or artery-vein, regardless of the thrombosis state). Major clinical events were encountered in 1.7% (15/870), 1.1% (3/265), and 0% of patients in US −/−, US −/+, and US +/+ group, respectively (P = 0.02 between US −/− and US +/+ group). In the US −/− group, 5/10 (50%) of pseudo-aneurysms were diagnosed during readmission after a mean of 24 ± 11 days post-procedure. No delayed presentation was seen in the US −/+ group. Major US events during the US protocol post-procedure were seen in 3.8% (10/265) vs. 0.3% (1/300) of patients in US −/+ vs. US +/+ group, respectively, P = 0.004. US-guided venipuncture was associated with a near-to-zero risk of vascular complications in our patients undergoing CB ablation.
- 11 July 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (3) , 434-439
Value of ultrasound for access guidance and detection of subclinical vascular complications in the setting of atrial fibrillation cryoballoon ablation
Vascular complications are the most common complications of atrial fibrillation (AF) ablation. Cryoballoon (CB) ablation for AF needs the insertion of a large 15 Fr sheath in the femoral vein. Our aim was to investigate the impact of vascular ultrasound (US) in guiding access and evaluating post-procedural subclinical complications in a large, multi-centre patient cohort that underwent CB ablation. A total cohort of 1435 consecutive patients were subdivided in 870 US −/−, 265 US −/+, and 300 US +/+ patients depending on US performance for: venipuncture guidance/post-procedural evaluation. Major clinical complications (requiring intervention and/or prolonged stay) were assessed. Irrespective of the clinical status, major US events were systematically determined in the subgroups with US evaluation 1 day post-procedure, if evidence of inadvertent artery puncture/cannulation (communication between artery and collection or artery-vein, regardless of the thrombosis state). Major clinical events were encountered in 1.7% (15/870), 1.1% (3/265), and 0% of patients in US −/−, US −/+, and US +/+ group, respectively (P = 0.02 between US −/− and US +/+ group). In the US −/− group, 5/10 (50%) of pseudo-aneurysms were diagnosed during readmission after a mean of 24 ± 11 days post-procedure. No delayed presentation was seen in the US −/+ group. Major US events during the US protocol post-procedure were seen in 3.8% (10/265) vs. 0.3% (1/300) of patients in US −/+ vs. US +/+ group, respectively, P = 0.004. US-guided venipuncture was associated with a near-to-zero risk of vascular complications in our patients undergoing CB ablation.
- 1 February 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 253, 78-81
Atrial fibrillation ablation with the second generation cryoballoon: Multicenter propensity score matched comparison between freezing strategies
- 1 February 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 253, 78-81
Atrial fibrillation ablation with the second generation cryoballoon: Multicenter propensity score matched comparison between freezing strategies